American Society of Clinical Oncology

SHERPA: White

People

  1. Postow
    Postow
  2. D'Angelo
    D'Angelo
  3. Dickson
    Dickson
  4. Gordon
    Gordon
  5. Montefusco
    Montefusco
  6. Panageas
    Panageas
  7. Abramson
    Abramson
  8. Bluth
    Bluth
  9. Harding
    Harding
  10. Ariyan
    Ariyan

Groups

  1. Department of Medicine (15)
  2. Melanoma and Immunotherapeutics Service (15)
  3. Solid Tumor Oncology Division (15)
  4. GSK Faculty (11)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  6. Melanoma Disease Management Team (5)
  7. Hematologic Malignancies, Division of (4)
  8. Advanced Practice Providers (3)
  9. Biostatistics Service (3)
  10. Epidemiology and Biostatistics (3)
Search Within
  1. "2012"
  2. "Melanoma and Immunotherapeutics Service"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (1)
Groups
  1. Department of Medicine (15)
  2. Melanoma and Immunotherapeutics Service (15)
  3. Solid Tumor Oncology Division (15)
  4. GSK Faculty (11)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  6. Melanoma Disease Management Team (5)

More Groups

People
  1. Jedd Wolchok (11)
  2. Paul Chapman (7)
  3. Jianda Yuan (4)
  4. Margaret Callahan (4)
  5. Michael Postow (4)
  6. Richard Carvajal (4)

More People

Years
  1. 2012 (15)
Publications
  1. Journal of Clinical Oncology (15)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study
    Meeting Abstract

    Thomas, L.; Wolchok, J. D.; Garbe, C.; Lebbe, C.; Bondarenko, I.; Rodrigues, K.; Konto, C.; Chin, K. M.; Francis, S.; Robert, C.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma
    Meeting Abstract

    Ribas, A.; Hodi, F. S.; Kurland, J. F.; Shahabi, V.; Francis, S.; Konto, C.; Joe, A. K.; Lainas, I.; Wolchok, J. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Evaluation of the absolute lymphocyte count as a biomarker for melanoma patients treated with the commercially available dose of ipilimumab (3mg/kg)
    Meeting Abstract

    Postow, M. A.; Yuan, J.; Panageas, K.; Bogatch, K.; Callahan, M.; Cheng, M.; Schroeder, S. E. A.; Kendle, R. F.; Harding, J. J.; Dickson, M. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma
    Meeting Abstract

    Kitano, S.; Postow, M. A.; Cortez, C.; Rasalan, T.; Gallardo, H. F.; Panageas, K.; Yuan, J.; Wolchok, J. D.; Lesokhin, A. M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)
    Meeting Abstract

    Kirkwood, J. M.; Long, G. V.; Trefzer, U.; Davies, M. A.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Kefford, R.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy
    Meeting Abstract

    Harding, J. J.; Lacouture, M. E.; Pulitzer, M.; Callahan, M.; Postow, M. A.; Carvajal, R. D.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Surgery for patients receiving ipilimumab: Safety profile and immunological insights
    Meeting Abstract

    Gyorki, D. E.; Yuan, J.; Mu, Z.; Zaidi, B.; Gallardo, H. F.; Brady, M. S.; Gutin, P. H.; Coit, D. G.; Wolchok, J. D.; Ariyan, C. E.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results
    Meeting Abstract

    Hamid, O.; Hwu, W. J.; Richards, J. M.; Weber, J. S.; Wolchok, J. D.; Sznol, M.; Minor, D. R.; Pavlick, A. C.; Urba, W. J.; Hodi, F. S.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma
    Meeting Abstract

    Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; Hamid, O.; Ascierto, P. A.; Testori, A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma
    Meeting Abstract

    Carvajal, R. D.; Ambrosini, G.; Wolchok, J. D.; Chapman, P. B.; Dickson, M. A.; D'Angelo, S. P.; Bluth, M. J.; Paucar, D.; Fusco, A.; Bohr, D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save